AGE-SPECIFIC, PROSTATE-SPECIFIC ANTIGEN (PSA) RANGES IN AFRICAN AMERICANS

非裔美国人的年龄特异性、前列腺特异性抗原 (PSA) 范围

• 批准号: 5209531
• 负责人: JOSEPH E OESTERLING
• 金额: --
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/5209531
• 关键词: African American; age difference; body weight; cancer risk; caucasian American; diagnosis design /evaluation; diet; dietary lipid; family genetics; human age group; human middle age (35-64); human old age (65+); human population study; human subject; interview; male; neoplasm /cancer diagnosis; obesity; prostate preneoplastic state; prostate specific antigen; questionnaires; racial /ethnic difference; urinary tract disorder

Prostate cancer is currently the most common cancer diagnosed and ranks second after lung cancer as the underlying cause of death among men in the United States. Current concerns about the control of prostate cancer have been directed toward early detection and intervention. Since 1987, the measurement of serum prostate-specific antigen (PSA) has led to dramatic increases in the detection of prostate cancer, presumably at earlier stages and at younger ages. Recent work has suggested that the measurement of different molecular forms of serum PSA in the peripheral circulation, or correcting PSA values for patient age, may enhance its diagnostic characteristics, however, most of our knowledge of these markers is based on Caucasian populations. Whereas the incidence and mortality rates of prostate cancer are significantly higher among African Americans than North American whites, it is currently unknown how serum PSA should be used in African-American men. It is our hypothesis that age-specific reference ranges and molecular forms of PSA will be similar in North American African Americans and whites (null hypothesis). To test this a random sample of approximately 500 healthy African-American men, 40-79 years of age inclusive, residing in Genesee County, Michigan, will be asked to participate in a cross-sectional, community-based study that will determine appropriate reference ranges for serum prostate-specific antigen (PSA). The age-specific distribution of free and complexed PSA, and PSA density (PSA/prostatic volume) will be assessed. Each subject will be evaluated for obstructive urinary tract symptoms, and examined by digital rectal (DRE) and transrectal ultrasonography (TRUS). Prior to the scheduled clinical examination, an interview will be conducted in the home of each participant using a standardized pre-tested questionnaire that will gather information on possible risk factors for prostate cancer and benign prostatic hyperplasia (BPH). At the time of the clinical examination, additional blood samples will be obtained and prepared for frozen storage in anticipation of future epidemiologic investigations. These studies will establish how serum PSA, new molecular forms of PSA, and PSA density should be interpreted in African Americans.

前列腺癌是目前诊断和排名最高的癌症 仅次于肺癌成为男性死亡的根本原因 美国。目前人们对前列腺癌控制的担忧 旨在及早发现和干预。自1987年以来， 血清前列腺特异性抗原(PSA)的检测导致了戏剧性的 前列腺癌的检测增加，估计是在更早的时候 在各个阶段和更年轻的时候。最近的研究表明， 外周血中不同分子形式PSA的检测 循环，或根据患者的年龄校正PSA值，可能会增强其 诊断特征，然而，我们对这些的大多数知识 MARKS以高加索人口为基础。鉴于发病率和 非洲人的前列腺癌死亡率要高得多 美国人比北美白人多，目前尚不清楚血清是如何 PSA应该用于非裔美国人。我们的假设是 特定年龄的PSA的参考范围和分子形式将是相似的 在北美非裔美国人和白人中(零假设)。为了测试 这是对大约500名健康的非裔美国男性的随机抽样， 40-79岁，居住在密歇根州杰纳西县，将 被邀请参加一项以社区为基础的横断面研究 将确定血清前列腺特异性的适当参考范围 抗原(PSA)。游离和复杂PSA的年龄分布， 并评估PSA密度(PSA/前列腺体积)。每个科目 将对梗阻尿路症状进行评估，并由 直肠指诊(DRE)和经直肠超声(TRUS)检查。在此之前 预定的临床检查，面谈将在家中进行 使用标准化的预测问卷对每个参与者进行评估 将收集有关前列腺癌可能的风险因素的信息，并 良性前列腺增生(BPH)。在临床试验的时候 检查，将获得额外的血液样本，并准备用于 冷冻储存，为未来的流行病学调查做好准备。 这些研究将确定血清PSA，PSA的新分子形式， 而PSA密度应该在非裔美国人中解释。